On Sept. 4, the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research approved a “first generic” ticagrelor tablet – 60 mg and 90 mg doses – for post acute coronary syndrome management.

“First generics” are the first approval by the FDA which permits a manufacturer to market a generic drug product in the U.S. The FDA approved AstraZeneca’s Brilinta (ticagrelor) for use in 60 mg doses in September 2015.

Keywords: ACC Publications, Cardiology Magazine, Drug Evaluation, United States Food and Drug Administration

< Back to Listings